Skip to main content
. Author manuscript; available in PMC: 2014 Mar 12.
Published in final edited form as: Clin Neuropharmacol. 2011 Nov-Dec;34(6):224–233. doi: 10.1097/WNF.0b013e318237709a

Table 4.

Change in AIMS, BARS and SAS scores over time

groups
Time pt. (n = 20) (n = 25) p-value Group Time Group*Time
AIMS Baseline 0.9(0.3) 0.9(0.3) 0.99 F(5,42)=2.8 F(5,134)=1.6 F(5,134)=0.2
1 month 0.5(0.3) 0.8(0.3) 0.48 P = NS P = NS P = NS
3 months 0.1(0.4) 0.4(0.3) 0.48
6 months 0.04(0.4) 0.4(0.3) 0.40
9 months 0.2(0.4) 0.8(0.3) 0.26
12 months 0.04(0.4) 0.5(0.3) 0.37
BARS Baseline 0.2(0.1) 0.4(0.1) 0.38 F(1,42)=0.2 F(5,136)=0.7 F(5,136)=0.7
1 month 0.4(0.2) 0.1(0.1) 0.19 P = NS P = NS P = NS
3 months 0.02(0.2) 0.3(0.2) 0.33
6 months 0.03(0.2) 0.07(0.2) 0.89
9 months 0.1(0.2) 0.3(0.2) 0.85
12 months 0.1(0.2) 0.04(0.2) 0.81
SAS Baseline 1.1(0.4) 1.0(0.3) 0.57 F(1,41)=3.3 F(5,131)=2.4 F(5,131)=2.5
1 month 0.7(0.4) 0.8(0.4) 0.99 P = NS P = 0.04 P = 0.04
3 months 0.8(0.5) 1.2(0.4) 0.58
6 months 0.7(0.5) 0.7(0.4) 0.92
9 months 0.6(0.6) 3.2(0.4)**** 0.0003
12 months 1.6(0.5) 1.8(0.4) 0.75

All values are LS-mean (SE) unless otherwise specified.

We used a mixed model repeated measures (MMRM) approach with time (baseline, 1-, 3-, 6-, 9-, 12-month visits) as the within-subjects factor and treatment (RLAI+TAU vs. TAU alone) as the between-subjects factor. Analyses were adjusted for baseline dependent measure values. Reported p-values reflect between-group differences at the corresponding time point. Statistically significant within-group changes at each time point (relative to baseline values) are represented with asterisks:

****

p ≤ 0.0001

*** p ≤ 0.001

** p≤0.01

* p < 0.05

p < 0.08 (trend) for within group comparison for each time point against the baseline values.